Healthcare provider profile · identity verified

Daniel Ring, MD

Family Practice · PHILADELPHIA, PA · NPI 1265966063

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	476	108
Metformin Hcl	Metformin Hcl	357	69
Lisinopril	Lisinopril	245	44
Famotidine	Famotidine	219	39
Albuterol Sulfate Hfa	Albuterol Sulfate	170	37
Amlodipine Besylate	Amlodipine Besylate	165	46
Jardiance	Empagliflozin	141	28
Losartan Potassium	Losartan Potassium	141	36
Tamsulosin Hcl	Tamsulosin Hcl	134	21
Gabapentin	Gabapentin	131	24
Levothyroxine Sodium	Levothyroxine Sodium	131	29
Trulicity	Dulaglutide	129	19
Omeprazole	Omeprazole	106	23
Rosuvastatin Calcium	Rosuvastatin Calcium	106	22
Fluticasone Propionate	Fluticasone Propionate	99	23
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	99	28
Metoprolol Succinate	Metoprolol Succinate	88	21
Hydrochlorothiazide	Hydrochlorothiazide	86	19
Montelukast Sodium	Montelukast Sodium	80	12
Carvedilol	Carvedilol	69	12
Mirtazapine	Mirtazapine	64	suppressed
Ibuprofen	Ibuprofen	56	12
Olmesartan Medoxomil	Olmesartan Medoxomil	50	17
Escitalopram Oxalate	Escitalopram Oxalate	48	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	47	suppressed
Naproxen	Naproxen	45	suppressed
Pravastatin Sodium	Pravastatin Sodium	45	11
Simvastatin	Simvastatin	39	suppressed
Nifedipine Er	Nifedipine	38	suppressed
Furosemide	Furosemide	36	suppressed
Januvia	Sitagliptin Phosphate	36	suppressed
Alcohol Swabs	Alcohol Antiseptic Pads	34	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	33	suppressed
Trazodone Hcl	Trazodone Hcl	32	suppressed
Unifine Safecontrol Pen Needle	Pen Needle,dual Safety,diabetc	32	suppressed
Xarelto	Rivaroxaban	31	suppressed
Trueplus Pen Needle	Pen Needle, Diabetic	30	suppressed
Farxiga	Dapagliflozin Propanediol	29	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	28	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	27	suppressed
Sertraline Hcl	Sertraline Hcl	27	suppressed
Alcohol Prep Pads	Alcohol Antiseptic Pads	26	suppressed
Diclofenac Sodium	Diclofenac Sodium	25	suppressed
Hydralazine Hcl	Hydralazine Hcl	24	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	24	suppressed
Ammonium Lactate	Ammonium Lactate	23	suppressed
Clopidogrel	Clopidogrel Bisulfate	23	11
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	21	suppressed
Donepezil Hcl	Donepezil Hcl	20	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	20	suppressed
Hydrocortisone	Hydrocortisone	19	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	19	suppressed
Chlorthalidone	Chlorthalidone	18	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	18	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	18	suppressed
Ozempic	Semaglutide	17	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	17	suppressed
Comfort Ez Pen Needle	Pen Needle, Diabetic	15	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	15	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	15	suppressed
Valsartan	Valsartan	15	suppressed
Alcohol Pads	Alcohol Antiseptic Pads	14	suppressed
Nystatin	Nystatin	14	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	13	suppressed
Bupropion Hcl Sr	Bupropion Hcl	13	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	13	suppressed
Easy Touch Alcohol Prep Pads	Alcohol Antiseptic Pads	13	suppressed
Sucralfate	Sucralfate	13	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	13	suppressed
Advair Hfa	Fluticasone Propion/Salmeterol	12	suppressed
Alendronate Sodium	Alendronate Sodium	12	suppressed
Citalopram Hbr	Citalopram Hydrobromide	12	suppressed
Clonazepam	Clonazepam	12	suppressed
Jentadueto	Linagliptin/Metformin Hcl	12	suppressed
Nyamyc	Nystatin	12	suppressed
Topiramate	Topiramate	12	suppressed
Verapamil Er	Verapamil Hcl	12	suppressed
Allopurinol	Allopurinol	11	suppressed
Divalproex Sodium Er	Divalproex Sodium	11	suppressed
Lidocaine	Lidocaine	11	suppressed
Metformin Hcl Er	Metformin Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error